Article

Hyper-CVAD Plus Sequential Blinatumomab With or Without Inotuzumab Elicits Clinical Benefit in Ph-Negative B-Cell ALL

Author(s):

Sequential administration of blinatumomab with or without inotuzumab following hyper-CVAD elicited high rates of minimal residual disease negativity and a durable overall survival benefit among patients with Philadelphia chromosome-negative B-cell acute lymphoblastic lymphoma.

Sequential administration of blinatumomab (Blincyto) with or without inotuzumab (Besponsa) following hyper-CVAD elicited high rates of minimal residual disease (MRD) negativity and a durable overall survival (OS) benefit among patients with Philadelphia chromosome (Ph)-negative B-cell acute lymphoblastic lymphoma (ALL), according to results from a phase 1/2 study (NCT01371630) presented at the 2022 ASCO Annual Meeting.1

Among all treated patients who received hyper-fractionated regimen of cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, and dexamethasone (hyper-CVAD) plus sequential blinatumomab with or without inotuzumab (n = 58) the MRD negativity rate was 95%. The 3-year OS rate among these patients was 84%.

Further, the efficacy findings show no relapses among patients without baseline high-risk features, and no relapses were observed beyond 2 years.

When stratified according to inotuzumab therapy, among those who received the additional treatment (n = 20) the MRD negativity rate was 90% compared with 97% among those who received sequential blinatumomab only (n = 38). The 1-year OS rates for these groups were 100% and 87%, respectively.

Outcomes with standard therapy for ALL include a long-term OS rate between 40% and 50% and a complete response (CR) rate between 80% and 90%. In comparison with chemotherapy, investigators know that blinatumomab plus inotuzumab has higher rates of MRD eradication, and by adding the combination to hyper-CVAD, it was hypothesized that patients would experience higher efficacy and rates of remission with less myelosuppression.

Fifty-eight patients with newly diagnosed Ph-negative B-cell ALL aged 14 to 59 years were enrolled in the study. The protocol allowed for prior treatment with no more than 1 cycle of induction chemotherapy. Patients were required to be eligible for intensive chemotherapy, have an ECOG performance status of 3 or less, adequate organ function defined as bilirubin 2 mg/dL or lower, and creatinine 2 mg/dL or lower. Patients were not permitted to have significant central nervous system pathology.

At baseline, the population had a median age of 34 years (range, 17-59), and the majority (81%) had an ECOG performance score of 0 or 1. The median baseline white blood cell count was 4.1 x 109/L (range, 0.5-553). CNS involvement at the time of diagnosis was observed in 10% of the study population. Fifty-five percent of patients had a CD20 expression of at least 20% and 98% had CD19 expression of at least 50%.

In terms of karyotype, diploid was most commonly identified (31%), followed by low hypodiploidy/near triploidy (14%), KMT2A rearrangement (9%) complex (7%), and high hyperdiploidy (7%). Thirty-three percent of patients had other karyotypes.

According to cytometry, 19% of patients in the study were CRLF2-positive. Also, 26% of patients tested positive for a TP53 mutation and 8% were positive for a JAK2 mutation.

Treatment in the intensive phase lasted for 4 weeks of therapy. Patients were treated with ofatumumab (Kesimpta) or rituximab (Rituxan) twice per week with hyper-CVAD, methotrexate plus 8 doses of cytarabine. Following the intensive phase, patients received blinatumomab on weeks 2 and 4. In the maintenance phase, patients received 6 doses of mercaptopurine plus vincristine, methotrexate, and prednisone (POMP) on days 1 to 3, 5 to 7, 9 to 11, and 13 to 15. Additionally, patients were treated with blinatumomab on days 4, 8, and 12 during the maintenance phase, and inotuzumab was administered at 0.3 mg/m2 on days 1 and 8.

After induction, CRs were observed in 80% of patients overall. The CR rate in patients treated with hyper-CVAD plus blinatumomab was 81% compared with 77% among patients treated with hyper-CVAD with sequential blinatumomab plus inotuzumab. MRD negativity after induction was observed in 76% of patients overall. The hyper-CVAD plus blinatumomab arm has a CR rate of 85% after induction vs 63% in the hyper-CVAD with sequential blinatumomab plus inotuzumab group.

The CR at any time was 100% in the overall population as well as in each treatment arm. MRD negativity at any time was 95% overall and 97% for the hyper-CVAD plus blinatumomab compared with 63% in the other treatment arm.

The 30-day mortality was 3% in the overall population, with all deaths occurring in the hyper-CVAD plus blinatumomab arm.

Median follow-up was 34 months (range, 16-61) in the hyper-CVAD plus blinatumomab arm. Of the 38 patients who achieved a CR in the hyper-CVAD plus blinatumomab arm, 5 patients had relapsed disease, 3 died, 13 went on to transplant, and 18 had ongoing CRs at the time of data cutoff.

Among patients treated with hyper-CVAD plus blinatumomab and inotuzumab, the median follow-up was 6 months (range, 3-14). Among the 20 patients who achieved a CR with the regimen, 5 went on to transplant and 15 had ongoing CRs at the time of data cutoff.

Only 1 patient in the study discontinued treatment with blinatumomab as a result of recurrent grade 2 neurotoxicity. There were no patients who discontinued inotuzumab due to adverse events, and no cases of hepatic veno-occlusive disease were observed.

Reference

Short NJ, Kantarjian H, Ravandi F, et al. A phase II study of hyper-CVAD with sequential blinatumomab (Blina), with or without inotuzumab ozogamicin (INO), in adults with newly diagnosed B-cell acute lymphoblastic leukemia (ALL). J Clin Oncol. 2022; 40(suppl 16):7034. doi:10.1200/JCO.2022.40.16_suppl.7034

Related Videos
Francine Foss, MD
David C. Fisher, MD
Farrukh Awan, MD
Minoo Battiwalla, MD, MS
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the role of genomic profiling in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the treatment goals in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss factors for picking intensive chemotherapy vs other regimens in acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss dose intensity and sequencing of CPX-351 in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss long-term data for CPX-351 in acute myeloid leukemia.
James K. McCloskey, MD, and Harry P. Erba, MD, PhD, discuss factors to help determine intensive chemotherapy fitness in acute myeloid leukemia.